세계의 희귀의약품 서비스 시장 보고서(2025년)

Orphan drug services refer to specialized healthcare and pharmaceutical support focused on facilitating the research, development, approval, and accessibility of medications for rare diseases, which affect a small and often underserved portion of the population. These services play a critical role in navigating complex regulatory and development processes, ensuring that essential therapies reach patients who have limited or no alternative treatment options.

The primary types of orphan drug services include congenital disease, genetic disease, tumors and cancer, chronic conditions, and others. Congenital diseases refer to medical conditions present from birth, caused by genetic abnormalities, developmental issues during pregnancy, or environmental factors affecting fetal development. These services are applied across therapeutic areas such as oncology, metabolic disorders, neurological disorders, hematology, infectious diseases, and others, serving both adult and pediatric patient populations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The orphan drugs service market research report is one of a series of new reports from The Business Research Company that provides orphan drugs service market statistics, including orphan drugs service industry global market size, regional shares, competitors with an orphan drugs service market share, detailed orphan drugs service market segments, market trends and opportunities, and any further data you may need to thrive in the orphan drugs service industry. This orphan drugs service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The orphan drugs service market size has grown rapidly in recent years. It will grow from $37.05 billion in 2024 to $43.40 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth during the historic period was driven by increasing prevalence of rare diseases, rising government support, expanding patient advocacy initiatives, growing focus on unmet medical needs, and increasing collaboration between healthcare providers and researchers.

The orphan drugs service market size is expected to see rapid growth in the next few years. It will grow to $80.62 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth during the forecast period is fueled by rising investment in biopharmaceutical research, growing demand for precision medicine, expanding adoption of advanced clinical trial designs, increasing venture capital funding, and greater emphasis on global regulatory harmonization. The primary trends in the forecast period include advancements in drug discovery platforms, innovation in cell and gene therapy services, integration of artificial intelligence in clinical trials, developments in biomarker-based patient selection, and adoption of digital health solutions for patient monitoring.

The increasing investment in rare diseases is expected to drive the growth of the orphan drugs service market in the coming years. Rare diseases are health conditions that affect a small portion of the population, typically fewer than 1 in 2,000 people. These conditions are often chronic, progressive, and can be life-threatening or disabling. The rise in investment is primarily driven by the growing recognition of unmet medical needs and the potential for substantial returns, supported by regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. Increased investment enhances orphan drug services by providing additional funding for research and development, enabling the creation of therapies for previously overlooked conditions. It accelerates the availability of drugs by supporting clinical trials, regulatory approvals, and improving patient access, thereby expanding treatment options for those with rare diseases. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that companies focused on rare disease drugs raised $7.1 billion in the first quarter of 2024, a significant 307% increase from the $1.8 billion raised during the same period in 2023. As a result, the growing investment in rare diseases is fueling the expansion of the orphan drugs service market.

Companies in the orphan drugs service market are increasingly focused on obtaining regulatory approvals to expedite the development and availability of treatments for rare diseases. Regulatory approvals are essential for legal testing, manufacturing, and marketing of drugs and treatments. For example, in February 2023, Askbio GmbH, a US-based gene therapy company, received orphan drug designation from the European Commission for AB-1003, a novel gene therapy for limb-girdle muscular dystrophy. This adeno-associated virus (AAV)-based therapy aims to restore FKRP enzyme activity in muscle cells through a single intravenous infusion. AB-1003 has also been granted orphan drug status by the U.S. Food and Drug Administration (FDA), along with rare pediatric disease and fast track designations, underscoring the critical unmet need. The therapy is currently undergoing a Phase 1/2 clinical trial (LION-CS101) to evaluate its safety and efficacy in adults with genetically confirmed limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In April 2025, Norgine B.V., a Netherlands-based pharmaceutical company, acquired Theravia Pharma for an undisclosed amount. This acquisition allows Norgine to strengthen its rare disease portfolio and accelerate its growth in the rare and specialty pharmaceuticals sector. By expanding its range of life-changing therapies for patients with high unmet medical needs in Europe and the Asia-Pacific region (ANZ), Norgine aims to become a leading partner in rare diseases. Theravia Pharma, based in France, specializes in rare diseases and orphan drug services.

Major players in the orphan drugs service market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics, Caidya Inc., and Cevidra Inc.

North America was the largest region in the orphan drugs service market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in orphan drugs service report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the orphan drugs service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The orphan drugs service market includes revenues earned by entities through clinical trial management, pharmacovigilance and safety monitoring, distribution and supply chain services, patient support and access programs, and data management and biostatistics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orphan Drugs Service Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on orphan drugs service market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orphan drugs service ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The orphan drugs service market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Congenital Disease; Genetic Disease; Tumors And Cancer; Chronic; Other Types
• 2) By Therapeutic Area: Oncology; Metabolic Disorders; Neurological Disorders; Hematology; Infectious Diseases; Other Rare Diseases
• 3) By Application: Aldult; Children
• Subsegments:
• 1) By Congenital Disease: Heart Defects; Cleft Lip And Palate; Spina Bifida; Down Syndrome
• 2) By Genetic Disease: Cystic Fibrosis; Huntington Disease; Sickle Cell Anemia; Muscular Dystrophy
• 3) By Tumors And Cancer: Leukemia; Lymphoma; Neuroblastoma; Sarcoma
• 4) By Chronic: Rare Metabolic Disorders; Rare Endocrine Disorders; Rare Cardiovascular Disorders; Rare Neurological Disorders
• 5) By Other Types: Rare Infectious Diseases; Rare Immunological Disorders; Rare Dermatological Conditions; Rare Ophthalmological Disorders
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Novartis AG; AstraZeneca PLC; The Bristol-Myers Squibb Company; GSK plc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; IQVIA Inc.; CSL Behring GmbH; Lonza Group AG; BioMarin Pharmaceutical Inc.; Fortrea Holdings Inc.; Medpace Inc.; Sarepta Therapeutics; Caidya Inc.; Cevidra Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Orphan Drugs Service Market Characteristics

3. Orphan Drugs Service Market Trends And Strategies

4. Orphan Drugs Service Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Orphan Drugs Service Growth Analysis And Strategic Analysis Framework

• 5.1. Global Orphan Drugs Service PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Orphan Drugs Service Market Growth Rate Analysis
• 5.4. Global Orphan Drugs Service Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Orphan Drugs Service Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Orphan Drugs Service Total Addressable Market (TAM)

6. Orphan Drugs Service Market Segmentation

• 6.1. Global Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital Disease
• Genetic Disease
• Tumors And Cancer
• Chronic
• Other Types
• 6.2. Global Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Metabolic Disorders
• Neurological Disorders
• Hematology
• Infectious Diseases
• Other Rare Diseases
• 6.3. Global Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aldult
• Children
• 6.4. Global Orphan Drugs Service Market, Sub-Segmentation Of Congenital Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heart Defects
• Cleft Lip And Palate
• Spina Bifida
• Down Syndrome
• 6.5. Global Orphan Drugs Service Market, Sub-Segmentation Of Genetic Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cystic Fibrosis
• Huntington Disease
• Sickle Cell Anemia
• Muscular Dystrophy
• 6.6. Global Orphan Drugs Service Market, Sub-Segmentation Of Tumors And Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Neuroblastoma
• Sarcoma
• 6.7. Global Orphan Drugs Service Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rare Metabolic Disorders
• Rare Endocrine Disorders
• Rare Cardiovascular Disorders
• Rare Neurological Disorders
• 6.8. Global Orphan Drugs Service Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rare Infectious Diseases
• Rare Immunological Disorders
• Rare Dermatological Conditions
• Rare Ophthalmological Disorders

7. Orphan Drugs Service Market Regional And Country Analysis

• 7.1. Global Orphan Drugs Service Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Orphan Drugs Service Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Orphan Drugs Service Market

• 8.1. Asia-Pacific Orphan Drugs Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Orphan Drugs Service Market

• 9.1. China Orphan Drugs Service Market Overview
• 9.2. China Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Orphan Drugs Service Market

• 10.1. India Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Orphan Drugs Service Market

• 11.1. Japan Orphan Drugs Service Market Overview
• 11.2. Japan Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Orphan Drugs Service Market

• 12.1. Australia Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Orphan Drugs Service Market

• 13.1. Indonesia Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Orphan Drugs Service Market

• 14.1. South Korea Orphan Drugs Service Market Overview
• 14.2. South Korea Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Orphan Drugs Service Market

• 15.1. Western Europe Orphan Drugs Service Market Overview
• 15.2. Western Europe Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Orphan Drugs Service Market

• 16.1. UK Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Orphan Drugs Service Market

• 17.1. Germany Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Orphan Drugs Service Market

• 18.1. France Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Orphan Drugs Service Market

• 19.1. Italy Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Orphan Drugs Service Market

• 20.1. Spain Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Orphan Drugs Service Market

• 21.1. Eastern Europe Orphan Drugs Service Market Overview
• 21.2. Eastern Europe Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Orphan Drugs Service Market

• 22.1. Russia Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Orphan Drugs Service Market

• 23.1. North America Orphan Drugs Service Market Overview
• 23.2. North America Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Orphan Drugs Service Market

• 24.1. USA Orphan Drugs Service Market Overview
• 24.2. USA Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Orphan Drugs Service Market

• 25.1. Canada Orphan Drugs Service Market Overview
• 25.2. Canada Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Orphan Drugs Service Market

• 26.1. South America Orphan Drugs Service Market Overview
• 26.2. South America Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Orphan Drugs Service Market

• 27.1. Brazil Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Orphan Drugs Service Market

• 28.1. Middle East Orphan Drugs Service Market Overview
• 28.2. Middle East Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Orphan Drugs Service Market

• 29.1. Africa Orphan Drugs Service Market Overview
• 29.2. Africa Orphan Drugs Service Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Orphan Drugs Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Orphan Drugs Service Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Orphan Drugs Service Market Competitive Landscape And Company Profiles

• 30.1. Orphan Drugs Service Market Competitive Landscape
• 30.2. Orphan Drugs Service Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Orphan Drugs Service Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Novartis AG
• 31.3. AstraZeneca PLC
• 31.4. The Bristol-Myers Squibb Company
• 31.5. GSK plc.
• 31.6. Eli Lilly and Company
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Amgen Inc.
• 31.9. IQVIA Inc.
• 31.10. CSL Behring GmbH
• 31.11. Lonza Group AG
• 31.12. BioMarin Pharmaceutical Inc.
• 31.13. Fortrea Holdings Inc.
• 31.14. Medpace Inc.
• 31.15. Sarepta Therapeutics

32. Global Orphan Drugs Service Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Orphan Drugs Service Market

34. Recent Developments In The Orphan Drugs Service Market

35. Orphan Drugs Service Market High Potential Countries, Segments and Strategies

• 35.1 Orphan Drugs Service Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Orphan Drugs Service Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Orphan Drugs Service Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer